Corrigendum to “Protective effects of cortex fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice” [Eur. J. Pharmacol. 666 (2011) 196–204] (European Journal of Pharmacology (2011) 666(1–3) (196–204), (S0014299911005516), (10.1016/j.ejphar.2011.05.021));Protective effects of cortex fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice

European Journal of Pharmacology

Volumn 666, Issue 1-3, 2011, Pages 196-204

  Li, Jian Mei ^a   Zhang, Xian ^a   Wang, Xing ^a   Xie, Yong Chang ^a   Kong, Ling Dong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Cortex fraxini coumarine; Hyperuricemia; Renal dysfunction; Renal organic ion transporter

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; COUMARIN DERIVATIVE; CREATININE; ESCULETIN; ESCULIN; FRAXETIN; FRAXIN; GLUCOSE TRANSPORTER 9; MEMBRANE PROTEIN; MESSENGER RNA; ORGANIC ANION TRANSPORTER 1; ORGANIC CARNITINE TRANSPORTER 1; ORGANIC CARNITINE TRANSPORTER 2; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; OTERACIL; UNCLASSIFIED DRUG; URATE TRANSPORTER 1; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG EFFECT; DRUG PROTEIN BINDING; FRAXINUS; HYPERURICEMIA; KIDNEY DYSFUNCTION; MALE; MORNING DOSAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; UPREGULATION; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 79959992835     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2022.174740     Document Type: Erratum

References (35)

1. N. Anzai, K. Ichida, P. Jutabha, T. Kimura, E. Babu, C.J. Jin, S. Srivastava, K. Kitamura, I. Hisatome, H. Endou, and H. Sakurai Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans J. Biol. Chem. 283 2008 26834 26838
2. S. Bibert, S.K. Hess, D. Firsov, B. Thorens, K. Geering, J.D. Horisberger, and O. Bonny Mouse GLUT9: evidences for a urate uniporter Am. J. Physiol. Renal Physiol. 297 2009 F612 F619
3. C.D.A. Brown, R. Sayer, A.S. Windass, J.S. Haslam, M.E. De Broe, P.C. D'Haese, and A. Verhulst Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling Toxicol. Appl. Pharm. 233 2008 428 438
4. J.J. Carroll, H. Coburn, R. Douglass, and A.L. Babson A simplified alkaline phosphotungstate assay for uric acid in serum Clin. Chem. 17 1971 158 160
5. M. Chonchol, M.G. Shlipak, R. Katz, M.J. Sarnak, A.B. Newman, D.S. Siscovick, B. Kestenbaum, J.K. Carney, and L.F. Fried Relationship of uric acid with progression of kidney disease Am. J. Kidney Dis. 50 2007 239 247 (Pubitemid 47095076)
6. T. Deguchi, Y. Kouno, T. Terasaki, A. Takadate, and M. Otagiri Differential contributions of rOat1 (Slc22a6) and rOat3 (Slc22a8) to the in vivo renal uptake of uremic toxins in rats Pharm. Res. 22 2005 619 627 (Pubitemid 40603260)
7. A. Dehghan, A. Köttgen, Q. Yang, S.J. Hwang, W.L. Kao, F. Rivadeneira, E. Boerwinkle, D. Levy, A. Hofman, B.C. Astor, E.J. Benjamin, C.M. van Duijn, J.C. Witteman, J. Coresh, and C.S. Fox Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide study Lancet 372 2008 1953 1961
8. A. Dehghan, M. Van-Hoek, E.J.G. Sijbrands, A. Hofman, and J.C.M. Witteman High serum uric acid as a novel risk factor for type 2 diabetes Diabetes Care 31 2008 361 362 (Pubitemid 351213351)
9. A. Enomoto, and H. Endou Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease Clin. Exp. Nephrol. 9 2005 195 205 (Pubitemid 41414118)
10. A. Enomoto, H. Kimura, A. Chairoungdua, Y. Shigeta, P. Jutabha, S.H. Cha, M. Hosoyamada, M. Takeda, T. Sekine, T. Igarashi, H. Matsuo, Y. Kikuchi, T. Oda, K. Ichida, T. Hosoya, K. Shimokata, T. Niwa, Y. Kanai, and H. Endou Molecular identification of a renal urate anion exchanger that regulates blood urate levels Nature 417 2002 447 452 (Pubitemid 34563537)
11. Y. Habu, I. Yano, A. Takeuchi, H. Saito, M. Okuda, A. Fukatsu, and K. Inui Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and rOCT2 Biochem. Pharmacol. 66 2003 1107 1114 (Pubitemid 37083607)
12. Y. Habu, I. Yano, M. Okuda, A. Fukatsu, and K. Inui Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney Biochem. Pharmacol. 69 2005 993 999 (Pubitemid 40312716)
13. D.R. Hahn, and M.W. Lee Coumarin glycoside from the stembark of Fraxinus sieboldiana var. angustata Saengyak Hakhoechi 14 1983 1 3
14. M. Hosoyamada, K. Ichida, A. Enomoto, T. Hosoya, and H. Endou Function and localization of urate transporter 1 in mouse kidney J. Am. Soc. Nephrol. 15 2004 261 268 (Pubitemid 38140766)
15. Q.H. Hu, C. Wang, J.M. Li, D.M. Zhang, and L.D. Kong Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement Am. J. Physiol. Renal. Physiol. 297 2009 F1080 F1091
16. M. Huls, J.J. van den Heuvel, H.B. Dijkman, F.G. Russel, and R. Masereeuw ABC transporter expression profiling after ischemic reperfusion injury in mouse kidney Kidney Int. 69 2006 2186 2193 (Pubitemid 43882105)
17. J.W. Jonker, and A.H. Schinkel Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3) J. Pharmacol. Exp. Ther. 308 2004 2 9 (Pubitemid 38090693)
18. H. Koepsell, and H. Endou The SLC22 drug transporter family Pflug. Arch. Eur. J. Phy. 447 2004 666 676 (Pubitemid 38241452)
19. L.D. Kong, J. Zhou, Y.L. Weng, J.M. Li, and C.H.K. Cheng Aesculin possesses potent hypouricemic action in rodents but is devoid of xanthie oxidase/dehydrogenase inhibitory activity Planta Med. 68 2002 175 178 (Pubitemid 34169417)
20. C. Li, A. Chen, X. Chen, X. Ma, and Z. Hu Non-aqueous capillary electrophoresis for separation and simultaneous determination of fraxin, esculin and esculetin in cortex fraxini and its medicinal preparations Biomed. Chromatogr. 19 2005 696 702 (Pubitemid 41723121)
21. M. Luo, F. Liu, J.D. Zuo, J.Y. Yu, L.J. Huang, L.F. Ye, and N.N. Xiong Explorative clinical trial on effect of relieving pain in treatment of patients with primary acute gouty arthritis by cortex fraxini total coumarin Chin. J. Clin. Pharmacol. 10 2005 475 479
22. H. Matsuo, T. Chiba, S. Nagamori, A. Nakayama, H. Domoto, K. Phetdee, P. Wiriyasermkul, Y. Kikuchi, T. Oda, J. Nishiyama, T. Nakamura, Y. Morimoto, K. Kamakura, Y. Sakurai, S. Nonoyama, Y. Kanai, and N. Shinomiya Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia Am. J. Hum. Genet. 83 2008 744 751
23. T.R. Merriman, and N. Dalbeth The genetic basis of hyperuricaemia and gout Joint Bone Spine. 78 2011 35 40
24. J.I. Nezu, I. Tamai, A. Oku, R. Ohashi, H. Yabuuchi, N. Hashimoto, H. Nikaido, Y. Sai, A. Koizumi, Y. Shoji, G. Takada, T. Matsuishi, M. Yoshino, H. Kato, T. Ohura, G. Tsujimoto, J. Hayakawa, M. Shimane, and A. Tsuji Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter Nat. Genet. 21 1999 91 94 (Pubitemid 29036290)
25. I. Ohno Uricosuric agent Nippon Rinsho. 66 2008 743 747
26. F. Preitner, O. Bonny, A. Laverrière, S. Rotman, D. Firsov, A. Da Costa, S. Metref, and B. Thorens Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy Proc. Natl. Acad. Sci. U. S. A. 106 2009 11501 11506
27. H. Saito Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications Pharmacol. Ther. 125 2010 79 91
28. Y. Shibayama, K. Ushinohama, R. Ikeda, Y. Yoshikawa, T. Motoya, Y. Takeda, and K. Yamada Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats Cancer Sci. 97 2006 1260 1266 (Pubitemid 44430654)
29. V. Vitart, I. Rudan, C. Hayward, N.K. Gray, J. Floyd, C.N. Palmer, S.A. Knott, I. Kolcic, O. Polasek, J. Graessler, J.F. Wilson, A. Marinaki, P.L. Riches, X. Shu, B. Janicijevic, N. Smolej-Narancic, B. Gorgoni, J. Morgan, S. Campbell, Z. Biloglav, L. Barac-Lauc, M. Pericic, I.M. Klaric, L. Zgaga, T. Skaric-Juric, S.H. Wild, W.A. Richardson, P. Hohenstein, C.H. Kimber, A. Tenesa, L.A. Donnelly, L.D. Fairbanks, M. Aringer, P.M. McKeigue, S.H. Ralston, A.D. Morris, P. Rudan, N.D. Hastie, H. Campbell, and A.F. Wright SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout Nat. Genet. 40 2008 437 442 (Pubitemid 351450879)
30. X. Wang, C.P. Wang, Q.H. Hu, Y.Z. Lv, X. Zhang, Z. OuYang, and L.D. Kong The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice J. Ethnopharmacol. 128 2010 107 115
31. C. Watanabe A clinical study of the glycosides from Fraxinus Folia. Pharmacol. Japon. 43 1974 18 20
32. O.M. Woodward, A. Köttgen, J. Coresh, E. Boerwinkle, W.B. Guggino, and M. Köttgen Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout Proc. Natl. Acad. Sci. U.S.A. 106 2009 10338 10342
33. I. Yamagami, Y. Suzuki, and K. Ito Pharmacologic studies on the components of Fraxinus japonica Nippon Yakurigaku Zasshi 64 1968 714 729
34. J.Y. Yu, N.N. Xiong, F. Liu, J.D. Zou, L.J. Huang, L.F. Ye, and M. Luo Clinical trial of cortex fraxini total coumarin in treating primary hyperuricaemia Chin. J. Clin. Pharmacol. 24 2008 3 5
35. L. Zhou, J. Kang, L. Fan, X.C. Ma, H.Y. Zhao, J. Han, B.R. Wang, and D.A. Guo Simultaneous analysis of coumarins and secoiridoids in Cortex Fraxini by high-performance liquid chromatography-diode array detection-electrospray ionization tandem mass spectrometry J. Pharm. Biomed. Anal. 47 2008 39 46